Scarica l'app Stockscreener
0.59
0.27%
0.0016
Pre-mercato:
.60
0.01
+1.69%
Precedente Chiudi:
$0.5884
Aprire:
$0.5784
Volume 24 ore:
67,424
Relative Volume:
0.02
Capitalizzazione di mercato:
$3.89M
Reddito:
-
Utile/perdita netta:
$-10.31M
Rapporto P/E:
-0.2531
EPS:
-2.3308
Flusso di cassa netto:
$-6.32M
1 W Prestazione:
+0.15%
1M Prestazione:
+9.26%
6M Prestazione:
-52.03%
1 anno Prestazione:
-55.30%
Intervallo 1D:
$0.5701
$0.605
Intervallo di 1 settimana:
$0.54
$0.6068
Portata 52W:
$0.4111
$2.34
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Nome
Galmed Pharmaceuticals Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Compare GLMD vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
0.59 | 3.89M | 0 | -10.31M | -6.32M | -2.3308 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-05-22 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | Iniziato | Craig Hallum | Buy |
| 2020-01-30 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-12-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-08-02 | Reiterato | Maxim Group | Buy |
| 2018-07-13 | Iniziato | Stifel | Buy |
| 2018-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-06-12 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2018-02-14 | Downgrade | Maxim Group | Buy → Hold |
| 2018-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-15 | Iniziato | ROTH Capital | Buy |
| 2017-08-08 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Reiterato | Maxim Group | Buy |
| 2016-08-01 | Reiterato | Maxim Group | Buy |
| 2016-07-06 | Ripresa | ROTH Capital | Buy |
| 2016-03-28 | Ripresa | H.C. Wainwright | Buy |
| 2015-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2015-05-06 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
Mostra tutto
Galmed Pharmaceuticals Ltd Borsa (GLMD) Ultime notizie
GLMD (Galmed Pharmaceuticals Ltd. Ordinary Shares) posts wider than expected Q4 2025 loss, shares dip nearly one percent.Meet Estimates - Xã Thanh Hà
Shmuel Nir Net Worth (2026) - GuruFocus
Amir Poshinski Net Worth (2026) - GuruFocus
Brueck Liat Nissimov Net Worth (2026) - GuruFocus
Doron Leib Cohen Net Worth (2026) - GuruFocus
Allen Baharaff Net Worth (2026) - GuruFocus
Yohai Stenzler Net Worth (2026) - GuruFocus
Guy Nehemya Net Worth (2026) - GuruFocus
Galmed Pharmaceuticals (GLMD) Stock: Beginner's Guide (Smart Money Outflows) 2026-04-15Most Discussed Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
Galmed Pharmaceuticals Ltd. and Ramot At Tel Aviv University Enter Research Collaboration Agreement - marketscreener.com
Galmed partners with Tel Aviv University on brain cancer therapy By Investing.com - Investing.com Australia
Galmed partners with Tel Aviv University on brain cancer therapy - Investing.com
Galmed Pharmaceuticals Teams with Tel Aviv University on Aramchol for Metastatic Brain Cancer - TipRanks
Galmed (NASDAQ: GLMD) and Tel Aviv University test Aramchol for brain cancer - Stock Titan
Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers - PR Newswire
GLMD SEC FilingsGalmed Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Galmed stock soars on brain-penetrating Aramchol formulation - MSN
Galmed Stock Soars On Brain-Penetrating Aramchol FormulationGalmed Pharmaceuticals (NASDAQ:GLMD) - Benzinga
Galmed Unveils Brain-Penetrant Aramchol Formulation, Expanding Flagship Drug Into CNS Diseases - TipRanks
Galmed Pharmaceuticals Maps Future with Aramchol Strategy - timothysykes.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol - The AI Journal
Is Galmed Pharmaceuticals (GLMD) Stock a Safe Investment | Price at $0.52, Down 1.03%Shared Trade Ideas - Newser
[EFFECT] Galmed Pharmaceuticals Ltd. SEC Filing - Stock Titan
Going concern doubts and funding limits in Galmed (NASDAQ: GLMD) 2025 20-F - Stock Titan
MEDIA ADVISORY – Minister LeBlanc, Secretary of State Long and Parliamentary Secretary Myles to highlight investments supporting the Canadian Armed Forces following achievement of the NATO 2% defence spending target - Weekly Voice
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - ChartMill
Ideas Watch: Is Galmed Pharmaceuticals Ltd stock a good dividend stock2026 Update & Entry and Exit Point Strategies - baoquankhu1.vn
Portfolio Update: Can Galmed Pharmaceuticals Ltd grow without dilution2026 Recap & Safe Entry Point Alerts - baoquankhu1.vn
GLMD Stock Price, Quote & Chart | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill
Sectors Review: Can Galmed Pharmaceuticals Ltd deliver consistent dividendsMarket Rally & Low Risk Growth Stock Ideas - baoquankhu1.vn
Galmed (GLMD) director David Sidransky reports initial share and option holdings - Stock Titan
Galmed (GLMD) CFO details Ordinary Share, option and RSU holdings - Stock Titan
[Form 3] Galmed Pharmaceuticals Ltd. In... - Stock Titan
Galmed Pharmaceuticals (NASDAQ: GLMD) CAO reports shares, options and RSUs - stocktitan.net
Galmed Pharmaceuticals Ltd. (GLMD) CSO details option holdings - Stock Titan
Galmed (GLMD) director Amir Poshinski details shares, RSUs and options - Stock Titan
Galmed Pharmaceuticals (GLMD) director Nir Shmuel details initial share and RSU holdings - Stock Titan
Aug Chart Watch: Will Galmed Pharmaceuticals Ltd. stock maintain dividend yieldShort Setup & Advanced Swing Trade Entry Plans - Naître et grandir
Smart Money: Is Galmed Pharmaceuticals Ltd stock a good dividend stockMarket Growth Review & Reliable Price Breakout Signals - baoquankhu1.vn
Galmed Pharmaceuticals Shares Edge Higher Following CEO’s Positive Update - MSN
Galmed Pharmaceuticals Shareholders Approve Proposal at Special Meeting - The Globe and Mail
Galmed Pharmaceuticals (NASDAQ: GLMD) shareholders back proposal at March 5 special meeting - Stock Titan
Galmed Pharmaceuticals Adjourns Special Shareholder Meeting for Lack of Quorum - TipRanks
Galmed Pharmaceuticals (GLMD) adjourns shareholder meeting and resets date - Stock Titan
GLMD.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
GLMD Should I Buy - Intellectia AI
Buyout Rumor: Will Galmed Pharmaceuticals Ltd benefit from government policyWeekly Trend Report & Fast Momentum Entry Tips - baoquankhu1.vn
GLMD PE Ratio & Valuation, Is GLMD Overvalued - Intellectia AI
Can Galmed Pharmaceuticals Ltd. ride the EV waveWeekly Trend Recap & Daily Profit Focused Screening - mfd.ru
Galmed Pharmaceuticals Ltd Azioni (GLMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):